Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Impact of Remission Induction Chemotherapy Prior to Allogeneic Stem Cell Transplantation in Relapsed and Poor-response Patients With AML

NCT02461537 is registered in ClinicalTrials.gov with DKMS gemeinnützige GmbH as lead sponsor.

NCT NCT02461537
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02461537 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Impact of Remission Induction Chemotherapy Prior to Allogeneic Stem Cell Transplantation in Relapsed and Poor-response Patients With AML
Lead sponsor
DKMS gemeinnützige GmbH
Phase
Phase 3
Overall status
Completed
Start date
September 17, 2015
Completion date
January 12, 2024
Enrollment
281 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia